Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?'was held in
Erice, Italy, on October 8–13, 2013, to bring together leading experts in the biology and …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy
metabolism and growth. There is now considerable evidence that these hormones and the …

In evolutionary terms, GH and intracellular STAT 5 signaling is a very old regulatory system.
Whereas insulin dominates periprandially, GH may be viewed as the primary anabolic …

The term PEGylation describes the modification of biological molecules by covalent
conjugation with polyethylene glycol (PEG), a non-toxic, non-immunogenic polymer, and is …

Pituitary tumors account for about 15% of primary intracranial neoplasms. Proliferation of
pituitary cells, which secrete hormones, may result in a spectrum of endocrine symptoms …

The insulin-like growth factor 1 (IGF1) signalling pathway has important roles in regulating
cellular proliferation and apoptosis. Converging results from epidemiological research and …

The WHO categorizes pituitary tumours as typical adenomas, atypical adenomas and
pituitary carcinomas, with typical adenomas constituting the major class. However, the WHO …

Acromegaly is an acquired disorder related to excessive production of growth hormone (GH)
and characterized by progressive somatic disfigurement (mainly involving the face and …